Last reviewed · How we verify
dual therapy
Dual therapy, marketed by José Antonio Mata Marín, holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The therapy's competitive advantage lies in its unique mechanism of action, which differentiates it from current treatments. The primary risk is the lack of revenue data, which may affect investment and market confidence.
At a glance
| Generic name | dual therapy |
|---|---|
| Also known as | DRV/c+3TC, DTG/3TC, Truvada® |
| Sponsor | José Antonio Mata Marín |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment (NA)
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. (PHASE2)
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- The RECLAIM Study. (NA)
- A Study of a Weight Loss Intervention in People With Endometrial Cancer (EARLY_PHASE1)
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) (PHASE3)
- An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dual therapy CI brief — competitive landscape report
- dual therapy updates RSS · CI watch RSS
- José Antonio Mata Marín portfolio CI